Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 22, 2025
Reporting Period: Event date April 22, 2025; Expected Closing Date April 23, 2025.
Business Context: The Company entered into a Securities Purchase and Registration Rights Agreement for a private placement of equity securities.
Key Financial Metrics
Transaction Details:
- Securities Issued: 406,818 shares of Common Stock and warrants to purchase 406,818 shares.
- Price Per Unit: $1.905 (combined price for share and warrant).
- Warrant Exercise Price: $1.905 per share.
- Warrant Expiration: April 23, 2030, or earlier upon approval of the CardiAMP Cell Therapy System by the Japanese Pharmaceuticals and Medical Devices Agency.
- Gross Proceeds: Approximately $775,000 (before transaction expenses).
- Use of Proceeds: General corporate purposes.
Financial Position: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses solely on the capital raise event.
Material Changes
Capital Structure Change: The Company will issue new common stock and warrants, resulting in dilution to existing shareholders upon closing.
Insider Participation: Members of the Board of Directors and executive officers participated in the private placement with the following approximate investments:
- Andrew Blank (Board Member): $250,000
- Simon H. Stertzer, M.D. (Board Member): $200,000
- Peter Altman, Ph.D. (CEO and Board Member): $50,000
- Bill Facteau (Board Member): $25,000
- Richard Krasno, Ph.D. (Board Member): $25,000
- David McClung (CFO): $25,000
Guidance, Outlook, and Risks
Outlook: The Company intends to use proceeds for general corporate purposes. The transaction is structured as an "at the market" offering under Nasdaq rules.
Registration Rights: The Company agreed to file a Registration Statement with the SEC by May 3, 2025, to allow for the resale of the shares and issuable shares. The Company must keep this statement effective until all registrable securities are sold, Rule 144 restrictions are lifted, or April 22, 2027.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to customary closing conditions.
- Regulatory Approval: Warrant expiration is contingent on regulatory approval of the CardiAMP Cell Therapy System in Japan.
- Unregistered Securities: Securities were issued pursuant to Section 4(a)(2) of the Securities Act and are not registered.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $775,000 gross proceeds.
- Review the full text of the Securities Purchase and Registration Rights Agreement (Exhibit 4.1) for specific covenants and termination provisions.
- Monitor the filing of the Registration Statement by the May 3, 2025 deadline.
- Assess the impact of the 406,818 new shares and potential warrant exercises on existing shareholder dilution.
- Track the status of the CardiAMP Cell Therapy System application with the Japanese Pharmaceuticals and Medical Devices Agency, as this affects warrant expiration.